CTMX

CytomX Therapeutics, Inc. is an innovative biopharmaceutical company headquartered in South San Francisco, California, dedicated to transforming cancer therapies through its proprietary Probody™ technology platform. This cutting-edge approach aims to deliver highly selective treatments that minimize off-tumor effects while maximizing targeted anti-tumor efficacy, thereby addressing significant unmet needs in oncology. With a robust pipeline of product candidates at various clinical stages, CytomX is strategically positioned to enhance patient outcomes and redefine treatment standards in the cancer care landscape. Moreover, the company's focus on strategic partnerships and collaborations bolsters its capacity for impactful advancements within the biopharmaceutical industry.